Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
3 Ιαν 2023 · This statement from the International Antiviral Society–USA updates recommendations for the use of antiretroviral drugs to treat adults with established HIV infection and to prevent HIV infection among persons at risk.
27 Ιαν 2021 · CABENUVA, a 2-drug co-packaged product of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside...
16 Ιουλ 2021 · These guidelines bring in the most recent guidance on HIV testing strategies - the entry point for HIV prevention and treatment - and include comprehensive guidance on infant diagnosis. Key recommendations are presented on rapid antiretroviral therapy (ART) initiation and the use of dolutegravir.
3 Ιαν 2023 · Options for preexposure prophylaxis include oral medications (tenofovir disoproxil fumarate or tenofovir alafenamide plus emtricitabine) and, for the first time, a long-acting injectable agent, cabotegravir.
21 Ιουν 2023 · The new generation of long-acting or extended-release antiretroviral drugs, including long-acting broadly neutralizing monoclonal antibodies, has great promise for advancing biomedical HIV ...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms...
